Table 3.
Management of women by histopathologic diagnosis
| Histopathologic diagnosis | Management | Row total | |||||
|---|---|---|---|---|---|---|---|
| No treatment indicated (row%) (column%) | Immediate management based on colposcopic impression (row%) (column%) | Delayed excisional treatment on a recall visit (row%) (column%) | |||||
| With ablation | With LLETZ | Completed | Pendinga | ||||
| <CIN2 | 1158 (88.7%) (100.0%) | 90 (6.9%) (78.9%) | 54 (4.1%) (69.2%) | 3c (0.2%) (12.0%) | 0 | 1305 (100%) | |
| CIN2 | Diagnosed on biopsy/LLETZ | 0 | 10 (40.0%) (8.8%) | 11 (44.0%) (14.1%) | 2 (8.0%) (8.0%) | 2 (8.0%) (16.7%) | 25 (100%) |
| Diagnosed on ECC | 0 | 0 | 0 | 8 (66.7%) (32.0%) | 4 (33.3%) (33.3%) | 12 (100%) | |
| CIN3 | Diagnosed on biopsy/LLETZ | 0 | 13 (38.2%) (11.4%) | 12 (35.3%) (15.4%) | 5 (14.7%) (20.0%) | 4 (11.8%) (33.3%) | 34 (100%) |
| Diagnosed on ECCb | 0 | 1 (16.7%) (0.9%) | 0 | 3 (50.0%) (12.0%) | 2 (33.3%) (16.7%) | 6 (100%) | |
| Cancer | Diagnosed on biopsy/LLETZ | 0 | 0 | 1d (20.0%) (1.3%) | 4 (80.0%) (16.0%) | 0 | 5 (100%) |
| Column total | 1158 (100%) | 114 (100%) | 78 (100%) | 25 (100%) | 12 (100%) | Grand total = 1387 | |
aRecall attempts are temporarily paused due to COVID-19 pandemic spread
bIncludes two women with OncoE6 HPV 16 positive, in whom LLETZ was recommended on recall and is still incomplete
cIncludes one case with colposcopic impression of cancer treated with hysterectomy of what eventually turned out to be <CIN2; other two cases were recalled for LLETZ due to reporting error
dInvasive squamous cell carcinoma with CIN3 at margins was diagnosed on on-site LLETZ leading to a recall for a repeat LLETZ with CIN3 diagnosis leading to a 2nd recall for a hysterectomy